BR112019003579A2 - Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos - Google Patents
Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativosInfo
- Publication number
- BR112019003579A2 BR112019003579A2 BR112019003579-6A BR112019003579A BR112019003579A2 BR 112019003579 A2 BR112019003579 A2 BR 112019003579A2 BR 112019003579 A BR112019003579 A BR 112019003579A BR 112019003579 A2 BR112019003579 A2 BR 112019003579A2
- Authority
- BR
- Brazil
- Prior art keywords
- nicotinamide
- compositions
- neurodegenerative disorders
- methods
- riboside
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378053P | 2016-08-22 | 2016-08-22 | |
| US62/378,053 | 2016-08-22 | ||
| PCT/US2017/047979 WO2018039207A1 (en) | 2016-08-22 | 2017-08-22 | Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019003579A2 true BR112019003579A2 (pt) | 2019-05-21 |
Family
ID=61246253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019003579-6A BR112019003579A2 (pt) | 2016-08-22 | 2017-08-22 | Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11260069B2 (https=) |
| EP (1) | EP3500267A4 (https=) |
| JP (1) | JP7132907B2 (https=) |
| KR (1) | KR20190046895A (https=) |
| CN (2) | CN115645432A (https=) |
| AU (1) | AU2017316614B2 (https=) |
| BR (1) | BR112019003579A2 (https=) |
| CA (1) | CA3034673A1 (https=) |
| MX (1) | MX2019002211A (https=) |
| RU (1) | RU2019108100A (https=) |
| WO (1) | WO2018039207A1 (https=) |
| ZA (1) | ZA201901536B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019003579A2 (pt) | 2016-08-22 | 2019-05-21 | Elysium Health, Inc. | Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos |
| US20200085849A1 (en) * | 2017-05-18 | 2020-03-19 | Elysium Health, Inc. | Methods and compositions for improving sleep |
| EP3642214A2 (en) | 2017-06-19 | 2020-04-29 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| CA3108015A1 (en) * | 2017-07-28 | 2019-01-31 | Centers For Age Control, Inc. | Compositions and methods for preventing and reversing aspects of aging |
| WO2020081923A1 (en) * | 2018-10-19 | 2020-04-23 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor |
| WO2020102326A1 (en) * | 2018-11-13 | 2020-05-22 | Elysium Health, Inc | Methods for determining and increasing nad levels |
| EP3897666A2 (en) | 2018-12-17 | 2021-10-27 | Mitopower LLC | Nicotinyl riboside compounds and their uses |
| US12350283B2 (en) | 2019-02-26 | 2025-07-08 | Universitat De Valencia-Estudi General | Methods and compositions for treating motor neuron diseases |
| CN110812365A (zh) * | 2019-11-07 | 2020-02-21 | 明特奇点医疗科技(北京)有限公司 | 一种组合物及其制备方法与制剂 |
| CN111838669B (zh) * | 2020-08-07 | 2022-11-29 | 四川大学华西医院 | 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途 |
| EP4029496A1 (en) * | 2021-01-18 | 2022-07-20 | Universitat de València | Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases |
| EP4079311B1 (en) | 2021-04-20 | 2025-10-01 | Nuvamid SA | Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism |
| EP4284387B1 (en) | 2021-06-24 | 2024-07-31 | Vestlandets Innovasjonsselskap As (Vis) | Nad-augmentation therapy for parkinson's disease |
| WO2022269064A1 (en) * | 2021-06-24 | 2022-12-29 | Vestlandets Innovasjonsselskap As (Vis) | Nad-augmentation therapy for parkinson's disease |
| CN118176006A (zh) * | 2021-10-27 | 2024-06-11 | 益力舒健康公司 | 治疗更年期综合征的方法 |
| WO2024259359A2 (en) | 2023-06-14 | 2024-12-19 | ChromaDex Inc. | Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof |
| CN116807985A (zh) * | 2023-06-20 | 2023-09-29 | 风火轮(上海)生物科技有限公司 | 一种烟酰胺核糖组合物及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1964627B (zh) * | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| EP2805719A1 (en) | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20090069444A1 (en) * | 2007-09-07 | 2009-03-12 | The United States Of America, As Represented By Th E Secretary Of Agriculture | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
| WO2009082459A2 (en) * | 2007-12-24 | 2009-07-02 | Natrol, Inc. | Anti-aging composition containing resveratrol and method of administration |
| WO2010095926A1 (en) | 2009-02-20 | 2010-08-26 | N.V. Nutricia | Use of reveratrol for preserving cognitive functioning |
| ES2798254T3 (es) | 2009-06-22 | 2020-12-10 | Indus Biotech Private Ltd | Proceso para la obtención de pteroestilbeno purificado y métodos de uso del mismo |
| EP2456772A4 (en) | 2009-07-24 | 2013-02-27 | Amazentis Sa | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONSERVING HEALTH HEALTH IN NEURODEEGENERATIVE DISEASES |
| US9439875B2 (en) | 2011-05-11 | 2016-09-13 | The United States Of America, As Represented By The Secretary Of Agriculture | Anxiolytic effect of pterostilbene |
| EP2574339A1 (de) | 2011-09-27 | 2013-04-03 | Johannes Huber | Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen |
| US20130149277A1 (en) | 2011-12-13 | 2013-06-13 | Cliffstar Llc | Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders |
| US20130296440A1 (en) | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
| CA2928656C (en) * | 2013-10-30 | 2020-07-28 | ChromaDex Inc. | Nicotinamide riboside compositions for topical use in treating skin conditions |
| KR20170012449A (ko) | 2014-06-02 | 2017-02-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 결정질 베타-d-니코틴아미드 리보시드의 제조 및 용도 |
| WO2016122832A1 (en) | 2015-01-30 | 2016-08-04 | Natural Formulations | Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries |
| US20180071273A1 (en) * | 2015-03-17 | 2018-03-15 | Speccialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
| BR112019003579A2 (pt) | 2016-08-22 | 2019-05-21 | Elysium Health, Inc. | Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos |
-
2017
- 2017-08-22 BR BR112019003579-6A patent/BR112019003579A2/pt not_active Application Discontinuation
- 2017-08-22 US US16/327,651 patent/US11260069B2/en active Active
- 2017-08-22 CN CN202211250881.3A patent/CN115645432A/zh active Pending
- 2017-08-22 CA CA3034673A patent/CA3034673A1/en active Pending
- 2017-08-22 WO PCT/US2017/047979 patent/WO2018039207A1/en not_active Ceased
- 2017-08-22 JP JP2019510843A patent/JP7132907B2/ja active Active
- 2017-08-22 AU AU2017316614A patent/AU2017316614B2/en active Active
- 2017-08-22 CN CN201780064669.9A patent/CN109982706A/zh active Pending
- 2017-08-22 MX MX2019002211A patent/MX2019002211A/es unknown
- 2017-08-22 RU RU2019108100A patent/RU2019108100A/ru not_active Application Discontinuation
- 2017-08-22 KR KR1020197008293A patent/KR20190046895A/ko not_active Ceased
- 2017-08-22 EP EP17844270.3A patent/EP3500267A4/en not_active Withdrawn
-
2019
- 2019-03-12 ZA ZA2019/01536A patent/ZA201901536B/en unknown
-
2022
- 2022-01-21 US US17/580,999 patent/US11998561B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7132907B2 (ja) | 2022-09-07 |
| JP2019524856A (ja) | 2019-09-05 |
| RU2019108100A3 (https=) | 2020-11-27 |
| ZA201901536B (en) | 2024-06-26 |
| MX2019002211A (es) | 2019-10-30 |
| AU2017316614A1 (en) | 2019-03-21 |
| KR20190046895A (ko) | 2019-05-07 |
| US11260069B2 (en) | 2022-03-01 |
| AU2017316614B2 (en) | 2023-06-15 |
| CA3034673A1 (en) | 2018-03-01 |
| CN109982706A (zh) | 2019-07-05 |
| WO2018039207A1 (en) | 2018-03-01 |
| RU2019108100A (ru) | 2020-09-22 |
| CN115645432A (zh) | 2023-01-31 |
| EP3500267A4 (en) | 2020-03-18 |
| EP3500267A1 (en) | 2019-06-26 |
| US20220143055A1 (en) | 2022-05-12 |
| US20190201426A1 (en) | 2019-07-04 |
| US11998561B2 (en) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019003579A2 (pt) | Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| EP4272834A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| CO2019013707A2 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson | |
| MX2022005225A (es) | Derivados de benzooxazol como inmunomoduladores. | |
| ZA201800056B (en) | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| BR112017007063A2 (pt) | ?composições e métodos para o tratamento de insônia? | |
| EP4289820A3 (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| CY1125113T1 (el) | Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας | |
| BR112017002260A2 (pt) | derivados de piperazina como moduladores do receptor x do fígado | |
| MX379359B (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| PT3302454T (pt) | Composições para utilização no tratamento da doença de parkinson e distúrbios associados | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| MX2022013283A (es) | Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales. | |
| IL265911A (en) | Epilimod preparations and methods of using them in the treatment of Alzheimer's disease | |
| WO2018013951A9 (en) | Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias | |
| EP3554496A4 (en) | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | |
| EP3634979A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS | |
| BR112017009599A2 (pt) | composições contendo apoaequorina e métodos de uso das mesmas para tratar inflamação neuronal | |
| ZA201806103B (en) | Compositions and methods for the treatment of sinus disease and disorders | |
| HK40013419A (en) | Apilimod compositions and methods for using same in the treatment of alzheimer's disease | |
| CO2019003858A2 (es) | Formulaciones de cisteamina y derivados de cisteamina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |